In a report issued on May 12, Robert Drbul from Guggenheim maintained a Buy rating on FIGS (FIGS – Research Report), with a price target of $20.00. The company’s shares closed last Friday at $9.64, close to its 52-week low of $9.23.
According to TipRanks.com, Drbul is a 5-star analyst with an average return of 8.8% and a 60.6% success rate. Drbul covers the Consumer Goods sector, focusing on stocks such as National Vision Holdings, Lululemon Athletica, and Columbia Sportswear.
FIGS has an analyst consensus of Moderate Buy, with a price target consensus of $25.60, which is a 171.0% upside from current levels. In a report issued on May 13, Credit Suisse also maintained a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on FIGS’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $129 million and net profit of $12.6 million. In comparison, last year the company earned revenue of $90.19 million and had a net profit of $12.13 million.
Based on the recent corporate insider activity of 40 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FIGS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle and moisture-wicking properties.
Read More on FIGS:
- Williams Trading Thinks Wolverine World Wide’s Stock is Going to Recover
- LifeSci Capital Sticks to Its Buy Rating for Better Therapeutics, Inc. (BTTX)
- William Blair Sticks to Their Buy Rating for Poseida Therapeutics (PSTX)
- Pyxis Oncology (PYXS) Gets a Buy Rating from William Blair
- William Blair Thinks Arcellx Inc’s Stock is Going to Recover
